Trial · NCT02564263
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus | Pembrolizumab | 8.2 | 95% Confidence Interval 6.7 to 10.3 | Months | |
| Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus | Chemotherapy | 7.1 | 95% Confidence Interval 6.1 to 8.2 | Months | |
| Overall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10) | Pembrolizumab | 9.3 | 95% Confidence Interval 6.6 to 12.5 | Months | |
| Overall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10) | Chemotherapy | 6.7 | 95% Confidence Interval 5.1 to 8.2 | Months | |
| Overall Survival (OS) in All Participants | Pembrolizumab | 7.1 | 95% Confidence Interval 6.2 to 8.1 | Months | |
| Overall Survival (OS) in All Participants | Chemotherapy | 7.1 | 95% Confidence Interval 6.3 to 8.0 | Months | |
| Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants | Pembrolizumab | 2.1 | 95% Confidence Interval 2.1 to 2.2 | Months | |
| Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants | Chemotherapy | 3.4 | 95% Confidence Interval 2.8 to 3.9 | Months | |
| Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants | Pembrolizumab | 13.1 | 95% Confidence Interval 9.5 to 17.3 | Percentage of Participants | |
| Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants | Chemotherapy | 6.7 | 95% Confidence Interval 4.2 to 10.0 | Percentage of Participants | |
| Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus | Pembrolizumab | 2.2 | 95% Confidence Interval 2.1 to 3.2 | Months | |
| Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus | Chemotherapy | 3.1 | 95% Confidence Interval 2.2 to 3.9 | Months | |
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10) | Pembrolizumab | 2.6 | 95% Confidence Interval 2.1 to 4.1 | Months | |
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10) | Chemotherapy | 3.0 | 95% Confidence Interval 2.1 to 3.7 | Months | |
| Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus | Pembrolizumab | 16.7 | 95% Confidence Interval 11.8 to 22.6 | Percentage of Participants | |
| Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus | Chemotherapy | 7.4 | 95% Confidence Interval 4.2 to 11.9 | Percentage of Participants | |
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10) | Pembrolizumab | 21.5 | 95% Confidence Interval 14.1 to 30.5 | Percentage of Participants | |
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10) | Chemotherapy | 6.1 | 95% Confidence Interval 2.5 to 12.1 | Percentage of Participants | |
| Number of Participants Experiencing an Adverse Event (AE) | Pembrolizumab | 301 | Participants | ||
| Number of Participants Experiencing an Adverse Event (AE) | Chemotherapy | 288 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02564263/results